A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer

Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis

“…After exclusion of duplicates and irrelevant studies, 8 reports were deemed to be eligible for the meta-analysis ( Figure 1). 13,[18][19][20][21][22][23][24] Of the 8 studies, 3 were multicenter RCTs (n ¼ 558) 13,18,19 and 5 were phase II or prospective series (n ¼ 224). [20][21][22][23][24] The characteristics of the studies included are reported in Supplemental Table 1 (available in the online version).…”

“…13,[18][19][20][21][22][23][24] Of the 8 studies, 3 were multicenter RCTs (n ¼ 558) 13,18,19 and 5 were phase II or prospective series (n ¼ 224). [20][21][22][23][24] The characteristics of the studies included are reported in Supplemental Table 1 (available in the online version). Patient age for inclusion was 70 or 75 years in 5 studies 13,[20][21][22][23] and 2 studies, 18,24 respectively, and 65 years in 1 trial.…”

“…[20][21][22][23][24] The characteristics of the studies included are reported in Supplemental Table 1 (available in the online version). Patient age for inclusion was 70 or 75 years in 5 studies 13,[20][21][22][23] and 2 studies, 18,24 respectively, and 65 years in 1 trial. 19 The major eligibility criteria are reported in Supplemental Table 2 (available in the online version).…”

Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review

“…The same regimen was used in another phase II study performed in elderly and frail patients. 32 No specific analysis was performed on the subgroup of elderly subjects, but they were known to be aged ≥70 years old, with a performance status of 1. The response rate was 40% (95% CI = 24.8%-55.2%) and the PFS was 7.2 months (95% CI = 4.4-12.1).…”

Current controversies in the management of metastatic colorectal cancer

“…Most trials are focused on good PS patients (PS ECOG 0-1), and patients with suboptimal PS (ECOG 2) or poor PS (ECOG > 2) are underrepresented or not included in clinical trials. When these patients with suboptimal or poor PS are included, worse tolerance and efficacy are usually observed [8,9]. Because of that, trials specifically focused on this suboptimal or poor PS population should be performed.…”